NCT07367971 Drug-Drug Interaction Study of ABP-671 in Gout Patients
| NCT ID | NCT07367971 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Atom Therapeutics Co., Ltd |
| Condition | Gout Chronic |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-01-23 |
| Primary Completion | 2026-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 20 participants in total. It began in 2026-01-23 with a primary completion date of 2026-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.
Eligibility Criteria
Inclusion Criteria: * Adults 18-75 years with clinical diagnosis of gout. * Stable Allopurinol therapy QD for ≥14 days prior to Day 1. * Cohort N: Normal renal function. * Cohort R: Moderate renal impairment. Exclusion Criteria: * Clinically significant hepatic impairment. * History of Allopurinol hypersensitivity. * Pregnancy or breastfeeding.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07367971 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Gout Chronic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07367971 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07367971 currently recruiting?
Yes, NCT07367971 is actively recruiting participants. Contact the research team at mao.e.sun@atombp.com for enrollment information.
Where is the NCT07367971 trial being conducted?
This trial is being conducted at Cary, United States.
Who is sponsoring the NCT07367971 clinical trial?
NCT07367971 is sponsored by Atom Therapeutics Co., Ltd. The trial plans to enroll 20 participants.